Keros Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Keros Therapeutics
KROS Stock  USD 18.18  0.38  2.05%   
Keros Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Keros Therapeutics' valuation are provided below:
Gross Profit
91.8 M
Profit Margin
0.2612
Market Capitalization
565.5 M
Enterprise Value Revenue
6.5 K
Revenue
246.7 M
There are over one hundred nineteen available fundamental ratios for Keros Therapeutics, which can be analyzed over time and compared to other ratios. All traders should check Keros Therapeutics' last-minute fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 693.2 M in 2026. Enterprise Value is likely to drop to about 545.9 M in 2026

Keros Therapeutics Total Revenue

3.04 Million

Check Keros Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Keros Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 663.6 K, Net Interest Income of 0.0 or Interest Income of 3.1 M, as well as many indicators such as Price To Sales Ratio of 143, Dividend Yield of 0.0 or PTB Ratio of 1.13. Keros financial statements analysis is a perfect complement when working with Keros Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Keros Stock
Check out the analysis of Keros Therapeutics Correlation against competitors.
For more information on how to buy Keros Stock please use our How to Invest in Keros Therapeutics guide.

Keros Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets743.7 M708.3 M207.5 M
Slightly volatile
Short and Long Term Debt Total22.8 M21.7 M7.1 M
Slightly volatile
Other Current Liabilities25.2 M24 M7 M
Slightly volatile
Total Current Liabilities16.2 M31.6 M14.3 M
Slightly volatile
Total Stockholder Equity690.2 M657.3 M185.5 M
Slightly volatile
Other Liabilities93.9 K55.8 K124.6 K
Slightly volatile
Property Plant And Equipment Net28.4 M27 M7.9 M
Slightly volatile
Current Deferred Revenue20.8 M19.8 M11.5 M
Slightly volatile
Accounts Payable3.4 M5.3 M2 M
Slightly volatile
Cash676.1 M643.9 M188.4 M
Slightly volatile
Non Current Assets Total32.6 M31 M9.3 M
Slightly volatile
Non Currrent Assets Other1.5 M2.4 M1 M
Slightly volatile
Other Assets4.2 M4 M1.5 M
Slightly volatile
Long Term Debt4 M5.7 M3.6 M
Slightly volatile
Cash And Short Term Investments676.1 M643.9 M188.4 M
Slightly volatile
Common Stock Total Equity2 K2.3 K1.5 K
Slightly volatile
Common Stock Shares Outstanding23.4 M43.1 M16.8 M
Slightly volatile
Long Term Debt Total4 M5.7 M3.6 M
Slightly volatile
Liabilities And Stockholders Equity743.7 M708.3 M207.5 M
Slightly volatile
Non Current Liabilities Total20.4 M19.4 M6.7 M
Slightly volatile
Capital Surpluse610.8 M581.7 M200.3 M
Slightly volatile
Capital Lease Obligations22.8 M21.7 M6 M
Slightly volatile
Other Current Assets29.6 M28.2 M6.4 M
Slightly volatile
Other Stockholder Equity1.4 B1.3 B339.4 M
Slightly volatile
Total Liabilities53.5 M51 M22 M
Slightly volatile
Property Plant And Equipment Gross31.9 M30.4 M8.6 M
Slightly volatile
Total Current Assets711.1 M677.2 M198.1 M
Slightly volatile
Capital Stock3.4 K3.6 K10.6 M
Slightly volatile
Non Current Liabilities Other15.5 M14.7 M5.4 M
Slightly volatile
Net Working Capital677.9 M645.7 M182.8 M
Slightly volatile
Short Term Debt2.4 M2.3 M662.1 K
Slightly volatile
Common Stock2.5 K4.6 K1.8 K
Slightly volatile
Property Plant Equipment1.8 M2.3 M1.6 M
Slightly volatile
Net Receivables4.7 M5.1 M2.6 M
Slightly volatile
Deferred Long Term Liabilities320 K360 K392.9 K
Slightly volatile

Keros Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income3.1 M3 M1.3 M
Slightly volatile
Depreciation And Amortization1.5 M1.4 M574.8 K
Slightly volatile
Selling General Administrative49.2 M46.9 M14.7 M
Slightly volatile
Total Revenue3 M3.2 M9 M
Slightly volatile
Other Operating Expenses258.9 M246.5 M73.5 M
Slightly volatile
Research Development209.7 M199.7 M59 M
Slightly volatile
Cost Of Revenue1.1 M1.1 M6.8 M
Slightly volatile
Total Operating Expenses258.9 M246.5 M73.5 M
Slightly volatile
Reconciled Depreciation1.5 M1.4 M462.1 K
Slightly volatile

Keros Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock101.1 M138.4 M60.7 M
Slightly volatile
Stock Based Compensation42.1 M40.1 M10.7 M
Slightly volatile
Begin Period Cash Flow401.3 M382.2 M115.9 M
Slightly volatile
Other Cashflows From Financing Activities9.2 M10.5 M11.3 M
Very volatile
Depreciation1.5 M1.4 M475.7 K
Slightly volatile
Other Non Cash Items1.5 M2.1 M860 K
Slightly volatile
Capital Expenditures1.2 M2.2 M739.3 K
Slightly volatile
Issuance Of Capital Stock459 M437.2 M121.1 M
Slightly volatile
Total Cash From Financing Activities473.1 M450.6 M120.2 M
Slightly volatile
End Period Cash Flow677.9 M645.6 M189 M
Slightly volatile
Change To Netincome22.6 M21.5 M7.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio143150958
Slightly volatile
PTB Ratio1.131.1929.8337
Very volatile
Days Sales Outstanding692412461
Slightly volatile
Book Value Per Share7.5813.745.8319
Slightly volatile
Stock Based Compensation To Revenue8.48.8424.109
Slightly volatile
Capex To Depreciation1.41.411.5527
Slightly volatile
PB Ratio1.131.1929.8337
Very volatile
EV To Sales12.4213.07684
Slightly volatile
Payables Turnover0.310.3211.293
Slightly volatile
Sales General And Administrative To Revenue9.8210.3329.2277
Slightly volatile
Research And Ddevelopement To Revenue41.8244.02114
Slightly volatile
Capex To Revenue0.470.492.0273
Slightly volatile
Cash Per Share7.7413.466.46
Slightly volatile
Days Payables Outstanding1.2 K1.2 K534
Slightly volatile
Net Debt To EBITDA3.183.3516.8126
Slightly volatile
Current Ratio13.2219.319.7659
Slightly volatile
Tangible Book Value Per Share7.5813.745.8319
Slightly volatile
Receivables Turnover0.870.926.6784
Slightly volatile
Shareholders Equity Per Share7.5813.745.8319
Slightly volatile
Debt To Equity0.03610.03790.1963
Very volatile
Capex Per Share0.03460.04640.034
Slightly volatile
Revenue Per Share0.10.110.7821
Slightly volatile
Interest Debt Per Share0.480.450.2058
Slightly volatile
Debt To Assets0.04180.03520.0337
Pretty Stable
Operating Cycle692412461
Slightly volatile
Price Book Value Ratio1.131.1929.8337
Very volatile
Days Of Payables Outstanding1.2 K1.2 K534
Slightly volatile
Ebt Per Ebit0.740.80.7722
Slightly volatile
Company Equity Multiplier1.181.242.898
Very volatile
Total Debt To Capitalization0.03490.03670.0849
Very volatile
Debt Equity Ratio0.03610.03790.1963
Very volatile
Quick Ratio13.2219.319.7659
Slightly volatile
Net Income Per E B T1.161.151.1466
Slightly volatile
Cash Ratio12.6718.369.3014
Slightly volatile
Days Of Sales Outstanding692412461
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.810.910.9726
Pretty Stable
Price To Book Ratio1.131.1929.8337
Very volatile
Fixed Asset Turnover0.170.15115.1581
Slightly volatile
Debt Ratio0.04180.03520.0337
Pretty Stable
Price Sales Ratio143150958
Slightly volatile
Asset Turnover0.00630.00660.2572
Slightly volatile
Price Fair Value1.131.1929.8337
Very volatile

Keros Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap693.2 M1.1 B561.4 M
Slightly volatile
Enterprise Value545.9 M768.7 M441.8 M
Slightly volatile

Keros Fundamental Market Drivers

Forward Price Earnings15.6495
Cash And Short Term Investments559.9 M

Keros Upcoming Events

1st of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
1st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Keros Therapeutics Financial Statements

Keros Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Keros Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Keros Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Keros Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue19.8 M20.8 M
Total Revenue3.2 M3 M
Cost Of Revenue1.1 M1.1 M
Stock Based Compensation To Revenue 8.84  8.40 
Sales General And Administrative To Revenue 10.33  9.82 
Research And Ddevelopement To Revenue 44.02  41.82 
Capex To Revenue 0.49  0.47 
Revenue Per Share 0.11  0.10 
Ebit Per Revenue(68.30)(71.71)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Keros Stock Analysis

When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY